206 related articles for article (PubMed ID: 35253361)
1. A pilot trial of prophylactic defibrotide to prevent serious thrombotic microangiopathy in high-risk pediatric patients.
Higham CS; Shimano KA; Melton A; Kharbanda S; Chu J; Dara J; Winestone LE; Hermiston ML; Huang JN; Dvorak CC
Pediatr Blood Cancer; 2022 May; 69(5):e29641. PubMed ID: 35253361
[TBL] [Abstract][Full Text] [Related]
2. Transplant-associated thrombotic microangiopathy in pediatric patients: pre-HSCT risk stratification and prophylaxis.
Higham CS; Collins G; Shimano KA; Melton A; Kharbanda S; Winestone LE; Huang JN; Dara J; Long-Boyle JR; Dvorak CC
Blood Adv; 2021 Apr; 5(8):2106-2114. PubMed ID: 33877298
[TBL] [Abstract][Full Text] [Related]
3. Increased Body Mass Index Augments Endothelial Injury and Clinical Outcomes after Hematopoietic Stem Cell Transplantation.
Koo J; Ziady AG; Reynaud D; Abdullah S; Luebbering N; Kahn S; Langenberg L; Strecker L; Lake K; Dandoy CE; Lane A; Myers KC; Sabulski A; Good S; Nalapareddy K; Solomon M; Siefert ME; Skala E; Jodele S; Davies SM
Transplant Cell Ther; 2023 Nov; 29(11):704.e1-704.e8. PubMed ID: 37625594
[TBL] [Abstract][Full Text] [Related]
4. Defibrotide in hematopoietic stem cell transplantation: A multicenter survey study of the Spanish Hematopoietic Stem Cell Transplantation Group (GETH).
González Vicent M; Díaz de Heredia C; González de Pablo J; Molina B; Regueiro A; Pérez Martinez A; Palomo P; López Corral L; García E; Fernández JM; Pérez A; Jiménez MJ; Guerreiro M; Vallejo C; Gallardo AI; López O; Benito A; Marsal J; Duarte M; Bento L; Badell I; Pedraza A; Jiménez Ubieto A; González P; Gómez Centurión I; Costilla L; Beléndez C; Esquirol A; Espigado I; Lavilla E; Díaz MÁ
Eur J Haematol; 2021 Jun; 106(6):842-850. PubMed ID: 33713387
[TBL] [Abstract][Full Text] [Related]
5. Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study.
Picod A; Bonnin A; Battipaglia G; Giannotti F; Ruggeri A; Brissot E; Malard F; Médiavilla C; Belhocine R; Vekhoff A; Gueye MS; Lapusan S; Adaeva R; Isnard F; Legrand O; Baylatry MT; Joly AC; Labopin M; Duléry R; Mohty M
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1471-1475. PubMed ID: 29477779
[TBL] [Abstract][Full Text] [Related]
6. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial.
Corbacioglu S; Cesaro S; Faraci M; Valteau-Couanet D; Gruhn B; Rovelli A; Boelens JJ; Hewitt A; Schrum J; Schulz AS; Müller I; Stein J; Wynn R; Greil J; Sykora KW; Matthes-Martin S; Führer M; O'Meara A; Toporski J; Sedlacek P; Schlegel PG; Ehlert K; Fasth A; Winiarski J; Arvidson J; Mauz-Körholz C; Ozsahin H; Schrauder A; Bader P; Massaro J; D'Agostino R; Hoyle M; Iacobelli M; Debatin KM; Peters C; Dini G
Lancet; 2012 Apr; 379(9823):1301-9. PubMed ID: 22364685
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics of pediatric allogeneic hematopoietic stem cell transplantation-associated thrombotic microangiopathy (TA-TMA): a retrospective single-center analysis.
Luo L; Xiong H; Chen Z; Yang L; Sun M; Lu W; Tao F; Wang Z; Li J; Li Z; Tang S
Clin Transl Oncol; 2023 Aug; 25(8):2451-2461. PubMed ID: 36973479
[TBL] [Abstract][Full Text] [Related]
8. Early Increase in Complement Terminal Pathway Activation Marker sC5b-9 Is Predictive for the Development of Thrombotic Microangiopathy after Stem Cell Transplantation.
Horváth O; Kállay K; Csuka D; Mező B; Sinkovits G; Kassa C; Stréhn A; Csordás K; Sinkó J; Prohászka Z; Kriván G
Biol Blood Marrow Transplant; 2018 May; 24(5):989-996. PubMed ID: 29339271
[TBL] [Abstract][Full Text] [Related]
9. The alternative complement pathway activation product Ba as a marker for transplant-associated thrombotic microangiopathy.
Sartain S; Shubert S; Wu MF; Wang T; Martinez C
Pediatr Blood Cancer; 2020 Mar; 67(3):e28070. PubMed ID: 31774252
[TBL] [Abstract][Full Text] [Related]
10. Hematopoietic stem cell transplant-associated thrombotic microangiopathy: review of pharmacologic treatment options.
Kim SS; Patel M; Yum K; Keyzner A
Transfusion; 2015 Feb; 55(2):452-8. PubMed ID: 25209960
[TBL] [Abstract][Full Text] [Related]
11. Transplantation-Associated Thrombotic Microangiopathy Risk Stratification: Is There a Window of Opportunity to Improve Outcomes?
Jodele S; Dandoy CE; Sabulski A; Koo J; Lane A; Myers KC; Wallace G; Chima RS; Teusink-Cross A; Hirsch R; Ryan TD; Benoit S; Davies SM
Transplant Cell Ther; 2022 Jul; 28(7):392.e1-392.e9. PubMed ID: 35490975
[TBL] [Abstract][Full Text] [Related]
12. Systematic Review of Signs and Symptoms Associated with Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy.
Dandoy CE; Tsong WH; Sarikonda K; McGarvey N; Perales MA
Transplant Cell Ther; 2023 Apr; 29(4):282.e1-282.e9. PubMed ID: 36592719
[TBL] [Abstract][Full Text] [Related]
13. New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCT.
Elfeky R; Lucchini G; Lum SH; Ottaviano G; Builes N; Nademi Z; Battersby A; Flood T; Owens S; Cant AJ; Young H; Greener S; Walsh P; Kavanagh D; Annavarapu S; Rao K; Amrolia P; Chiesa R; Worth A; Booth C; Skinner R; Doncheva B; Standing J; Gennery AR; Qasim W; Slatter M; Veys P
Blood Adv; 2020 Jun; 4(11):2418-2429. PubMed ID: 32492158
[TBL] [Abstract][Full Text] [Related]
14. Risk Factors for Transplant-Associated Thrombotic Microangiopathy after Autologous Hematopoietic Cell Transplant in High-Risk Neuroblastoma.
Tolbert VP; Dvorak CC; Golden C; Vissa M; El-Haj N; Perwad F; Matthay KK; Vo KT
Biol Blood Marrow Transplant; 2019 Oct; 25(10):2031-2039. PubMed ID: 31199983
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology and outcomes of pediatric transplant-associated thrombotic microangiopathy in Hong Kong.
Chan WYK; Ma ALT; Chan EYH; Kan ANC; Ng WF; Lee PPW; Cheuk DKL; Chiang AKS; Leung W; Chan GCF
Pediatr Transplant; 2022 Nov; 26(7):e14366. PubMed ID: 35860972
[TBL] [Abstract][Full Text] [Related]
16. Thrombotic Microangiopathy Following Pediatric Autologous Hematopoietic Cell Transplantation: A Report of Significant End-Organ Dysfunction in Eculizumab-Treated Survivors.
Schoettler M; Lehmann L; Li A; Ma C; Duncan C
Biol Blood Marrow Transplant; 2019 May; 25(5):e163-e168. PubMed ID: 30639820
[TBL] [Abstract][Full Text] [Related]
17. A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury.
Jodele S; Laskin BL; Dandoy CE; Myers KC; El-Bietar J; Davies SM; Goebel J; Dixon BP
Blood Rev; 2015 May; 29(3):191-204. PubMed ID: 25483393
[TBL] [Abstract][Full Text] [Related]
18. High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma.
Jodele S; Dandoy CE; Myers K; Wallace G; Lane A; Teusink-Cross A; Weiss B; Davies SM
Bone Marrow Transplant; 2018 Oct; 53(10):1311-1318. PubMed ID: 29674658
[TBL] [Abstract][Full Text] [Related]
19. High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease.
Kraft S; Bollinger N; Bodenmann B; Heim D; Bucher C; Lengerke C; Kleber M; Tsakiris DA; Passweg J; Tzankov A; Medinger M
Bone Marrow Transplant; 2019 Apr; 54(4):540-548. PubMed ID: 30108323
[TBL] [Abstract][Full Text] [Related]
20. Late transplant-associated thrombotic microangiopathy verified in bone marrow biopsy specimens is associated with chronic GVHD and viral infections.
Hill W; Sotlar K; Hautmann A; Kolb HJ; Ullmann J; Hausmann A; Schmidt M; Tischer J; Pham TT; Rank A; Hoechstetter MA
Eur J Haematol; 2024 May; 112(5):819-831. PubMed ID: 38243840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
